Please cite this article as: M.R. Hudson, E. Sokolenko, T.J. O'Brien, et al., NMDA receptors on parvalbumin-positive interneurons and pyramidal neurons both contribute to MK-801 induced gamma oscillatory disturbances: Complex relationships with behaviour, Neurobiology of Disease(2018), https://doi.
Introduction
Schizophrenia is a complex neuropsychiatric disorder characterised by a range of symptoms, including disturbances to sensory and cognitive processes. Whilst the underlying pathophysiology of the disorder is poorly understood, the widespread nature of the deficits observed has resulted in the conceptualisation of schizophrenia as a disorder of neuronal networks (Uhlhaas and Singer, 2010) . Of particular importance, gamma frequency oscillations (30-80Hz) have gained significant attention due to an accretion of evidence implicating their involvement in sensory and cognitive processes that are disturbed in schizophrenia (Lee et al., 2003; Uhlhaas and Singer, 2010) . Numerous studies have documented gamma oscillatory abnormalities in patients with schizophrenia, with complex and somewhat contradictory findings. Observations typically fall into two categories depending on the experimental paradigm: (1) several studies have reported deficits in transient elevations in gamma oscillations in response to sensory stimulation, referred to as evoked gamma activity, and (2) others have reported increases in the level of ongoing or background gamma oscillatory activity in schizophrenia patients (reviewed in (Hunt et al., preclinical model which attempts to replicate this hypofunction involves treatment of NMDAr antagonists to rodents (Adell et al., 2012) . This causes a variety of behavioural effects, including hyperlocomotion, stereotypic behaviour, cognitive deficits and sensorimotor gating impairments, features which are considered behavioural endophenotypes of schizophrenia (van den Buuse, 2010) . In addition, NMDAr antagonists also cause profound disturbances to gamma oscillatory activity. Specifically, they increase ongoing gamma oscillatory activity in rodents (Hakami et al., 2009; Jones et al., 2012; Pinault, 2008) , and reduce sensory-evoked gamma band responses (Kulikova et al., 2012; Saunders et al., 2012b) , similar to observations made in schizophrenia patients (Uhlhaas and Singer, 2010) .
Previous research with this pharmacological model has suggested that these alterations in gamma oscillatory activity are intricately tied to certain behavioural abnormalities. For instance, we have shown that the evoked gamma response elicited during prepulse inhibition assessment is directly related to sensorimotor gating behaviour (Hudson et al., 2016; Jones et al., 2014) . This suggests that alterations in evoked gamma power can influence sensory perception and integration of the triggering stimulus to impact behaviour.
In addition, correlative evidence links hyperlocomotor activity in this model to increases in ongoing gamma power (Hakami et al., 2009) , and have shown that antipsychotic drugs concurrently reduce both of these measures (Anderson et al., 2014; Jones et al., 2012) . The neural mechanisms which underlie this specific relationship are not clear. However, since peak locomotor activity correlates well with elevations in striatal ongoing gamma activity (Masimore et al., 2005; Nicolas et al., 2011) , and since the basal-ganglia and neocortex are involved in motor control, it is feasible that NMDAr hypofunction is driving gamma oscillations within these centres to promote hyperlocomotor activity.
The cellular mechanisms, and the mediating cell types, responsible for these electrophysiological disturbances of NMDAr antagonists to gamma oscillatory activity are J o u r n a l P r e -p r o o f Journal Pre-proof not conclusively established. One popular circuit model of gamma oscillatory activity, referred to as PING (Pyramidal-Interneuron-Network-Gamma), proposes that gamma oscillations arise due to the reciprocal interaction between fast-spiking parvalbumin-positive (PV+) interneurons and pyramidal neurons (Tiesinga and Sejnowski, 2009 ). As such, NMDAr hypofunction at either of these cell types could contribute to the disturbances in gamma oscillatory activity induced by NMDAr antagonists. The precise role of NMDAr on PV+ cells is not entirely clear and an area of contention amongst researchers. Gamma oscillations are a high-frequency network phenomena with a cycle duration of ~10-30ms. Of note, NMDAr currents are relatively long duration (~100-400ms) (Cull-Candy and Leszkiewicz, 2004; Hestrin et al., 1990) , promoting suggestions that this makes them intrinsically unable to play a direct role in the fast synaptic processes which underlie gamma oscillatory activity (Rotaru et al., 2012) . This is supported by results from computational models which suggest that the long-lasting nature of these currents causes increases in asynchronous firing and consequently reductions in gamma oscillatory power (Gonzalez-Burgos and Lewis, 2012). However, there is evidence which supports a role for NMDAr on PV+ neurons in normal gamma oscillatory dynamics. For instance, ablation of NMDAr from PV+ neurons disrupts the ability for gamma oscillations to be optogenetically stimulated which suggests that NMDAr on PV cells do play an important role in gamma activity (Carlen et al., 2012) . On the other hand, whether NMDAr on pyramidal neurons play a role in gamma oscillatory activity is not entirely clear. Although there is evidence to suggest that this may be the case (Tatard-Leitman et al., 2015) , based on current circuit models of gamma oscillatory activity, it is not clear how this might be achieved.
Given these uncertainties pertaining to the cellular basis of NMDAr antagonist induced disturbances to gamma oscillatory activity and behaviour, the present study set out to assess the contribution of NMDA receptors on both PV+ interneurons and pyramidal J o u r n a l P r e -p r o o f Journal Pre-proof neurons to these measures. Our approach involved generating two separate transgenic mouse lines in which cell-type specific deletion of the obligatory NMDA receptor subunit (GluN1) in parvalbumin positive neurons (PV:GluN1 KO mice) and pyramidal neurons (CaMKIIα:GluN1 KO mice) was achieved. The rationale behind this approach was that if certain electrophysiological and behavioural deficits were mediated by the actions of NMDAr antagonists directly on PV+ neurons or pyramidal neurons, then these outcomes would be attenuated or absent in mice lacking NMDA receptors on these cells.
While the focus of the current study was to elucidate the cellular substrate driving the effects of NMDAr antagonists, it is important to consider that GluN1 ablation itself could influence the neural circuits responsible for gamma oscillatory activity and behaviour.
Indeed, GluN1 deletion could be conceived as mimicking the very state of NMDAr hypofunction (albeit, in a cell-type specific manner) which we are modelling with NMDAr antagonists. In this regard, one might expect similar electrophysiological and behavioural perturbations in mice lacking GluN1 to those produced by NMDAr antagonists. However, previous literature using these mouse models (Bygrave et al., 2016) has reported only mild, if any, behavioural and electrophysiological phenotypes with relevance to schizophrenia. Given this, we predicted minimal behavioural or electrophysiological consequences of GluN1 deletion from either PV cells or CaMKII cells.
Materials and Methods

Animals
We sourced PV-Cre mice (JAX: 008069) and CaMKIIα-Cre mice (Casanova et al., 2001) from our colonies at the Melbourne Brain Centre, and purchased GluN1 floxed mice from Jackson labs (Stock: 005246). To generate the desired genotypes, we conducted a series of crossbreeds. The final genotypes, and their littermate controls were: PV-Cre/wt; wt/wt J o u r n a l P r e -p r o o f Journal Pre-proof (referred to as WT; total n=28) and PV-Cre/wt; GluN1fl/fl (herein referred to as PV:GluN1 KO; total n=26) and CaMKIIα-Cre/wt; wt/wt (referred to as WT; total n=20) x CaMKIIα-Cre/wt;GluN1fl/fl (referred to as CaMKIIα:GluN1 KO; total n=25). These breeding schedules were the same as previously described for these two transgenic mice lines (Billingslea et al., 2014; Tatard-Leitman et al., 2015) . All breeding took place at the Melbourne Brain Centre, University of Melbourne. The facility was maintained on a 12 h light/dark cycle (0730-1930h) with food and water available ad libitum. Only male mice (12-16 weeks old) were used for subsequent experiments. Mice were housed in groups of 2-5 throughout behavioural testing, and were individually housed following electrode implantation and subsequent electrophysiological recordings to avoid experimental loss. All the experimental procedures were approved by the Florey Institute Animal Ethics Committee (#15-045)
Acoustic startle and prepulse inhibition (PPI)
PPI was measured using an SR-Lab acoustic startle chamber (San Diego Instruments). The sessions consisted of pulse-alone trials (PA, 115dB startle pulse of 40ms duration) and prepulse+pulse trials (PP, prepulse stimulus of varying amplitude (72, 74, 78, 82 or 86dB) and 20ms duration which preceded the startle pulse by 100ms). Background noise was set at 70dB. Within a given session, trials were presented in a pseudorandom order with an average inter-trial interval of 15s. Mice were administered MK-801 (1.0mg/kg, i.p) or saline (0.9%, i.p) and subsequently placed into the chambers. The startle responses for each trial were recorded, and average startle magnitudes were calculated by averaging the amplitude of all Journal Pre-proof differences were observed between treatments, and so we presented the average %PPI across all prepulse intensities. In addition, a block of pulse alone trials were presented at the start and end of each session to enable calculation of startle habituation [100 x (first block average last block average)/first block average] (Geyer and Braff, 1982) .
Locomotor activity assay
Activity in a novel open field was measured in photo-beam activity arenas (E63-10, TruScan Coulbourn Instruments, Allentown, PA, USA). Mice were initially placed in the open field for 15 minutes to record baseline activity, after which they were briefly removed, administered MK-801 (0.1,0.3 or 1.0mg/kg, i.p) or saline (0.9%, i.p) and subsequently replaced for a further 60 minutes of recording in the same boxes. Whereas a single dose was used for PPI assessment, a dose-response analysis was performed for locomotion analysis as MK-801 has been shown to elicit opposite effects on locomotor activity dependent on dose, with relatively low doses causing an increase in locomotion but following higher doses, ataxic and cataleptic behaviours become the predominant phenotype.
For the PV:GluN1 KO cohort, in addition to measures of locomotor activity, mice were visually monitored for assessment of other behaviours such as stereotypies, ataxia, and catalepsy. We developed a 3 point scale for each of these (Table 1) . A score for each measure was given for each 5 minute block and these scores were subsequently averaged over 60 minutes post-injection.
Electrode implantation surgery
Following behaviour, mice underwent electrode implantation surgery to facilitate electrophysiological measurements (Hudson et al., 2018) . To enable recording of local field potentials (LFP), mice were implanted with 2 depth recording electrodes. Surgery was J o u r n a l P r e -p r o o f Journal Pre-proof conducted as previously described, with modifications (Jones et al., 2017; Jones et al., 2018) .
Briefly, animals were anaesthetised with isoflurane and the head was secured in a stereotaxic frame. Holes were drilled into the skull to allow implantation of stainless steel electrodes (diameter: 125µm, PlasticsOne, BioScientific NSW, Australia). Active electrode positioning was achieved using stereotactic guidance into the left prelimbic cortex (-0.4 (ML); +1.9 (AP); -1.9 (DV) relative to dura) and left dorsal hippocampus (-1.3; -1.8; -1.3). The reference electrode was implanted overlying the dura of the cerebellum. A custom-made ground electrode (0.5mm stainless steel screw with 125µm stainless steel wire soldered to one end) was implanted overlying the dura of the cerebellum. All electrodes were connected to a 4 channel connector (Part # M52-5002545, Element 14, Australia) and the whole assembly was covered and secured with dental acrylic (Vertex Dental, Netherlands). Animals were allowed to recover for at least 7 days prior to experimentation.
Electrophysiology studies
To record LFPs, a custom-made 4 channel cable was connected to the mouse's headpiece and the signal was amplified and then digitized using a PowerLab A-D converter and bioamplifiers (ADInstruments, Bella Vista, NSW, Australia). LabChart v4.5 Software (ADInstruments) was used to record the digitized signal at a sampling rate of 1000Hz.
Electrical noise from power mains (50Hz) was controlled using selective eliminators (Humbugs; Digitimer, Letchworth Garden City, UK).
For the recording sessions, mice were placed in a clear plexiglass cylinder to restrict movement and the cylinder was placed in a sound attenuated and electrically shielded chamber fitted with a calibrated speaker (San Diego Instruments). All electrophysiological recordings were conducted in animals in a quiet, awake behavioural state. Auditory stimuli (20ms, 85dB) were delivered using SR-LAB Startle Software (San Diego Instruments) every J o u r n a l P r e -p r o o f Journal Pre-proof 6 seconds against a background noise level of 70dB. Mice were allowed to habituate to the chamber for at least 5 minutes and then baseline activity was recorded for 20 minutes after which they were subsequently removed from the chamber to allow for intraperitoneal injection of MK-801 (1mg/kg i.p.) or saline. Mice were immediately returned to the chambers and after a further 10 minutes presented with auditory stimuli (85dB, 20ms) every 6s for 40 minutes. These sessions were then analysed as described below.
Ongoing Oscillatory Power
LFP data were processed using custom-designed MATLAB scripts (v7.10, Natick, MA, USA; The Mathworks, 2010). For spectral power analyses (Lee et al., 2017) , the raw data from 10 to 30 minutes following injection from each channel was first segmented into 10-s epochs and subject to a custom-made algorithm in MATLAB to remove any epochs containing appreciable levels of 50Hz noise. Following automatic artefact removal, the remaining epochs were then visually inspected for any additional artefacts including movement artefacts (and rejected if necessary). Power spectral density (PSD) estimation was then performed on the remaining clean epochs using the Welch Periodogram and was estimated using a fast Fourier transform and a Hamming window, to achieve a frequency resolution of 0.5HZ overlying the interval 1-100Hz. Normalised power (ie relative power) of delta (1-4Hz), theta (5-10Hz), beta (12-30Hz) and gamma (30-80Hz) frequencies were then calculated by taking the integral of the PSD estimate over the appropriate frequency interval and dividing by total power (1-100Hz).
Auditory evoked oscillatory activity
To analyse evoked oscillatory power, single trial epochs (-500ms to 500ms relative to onset of auditory stimuli) were extracted from the continuous LFP data for every stimulus. Epochs J o u r n a l P r e -p r o o f were visually inspected and any epochs containing notable artefacts were rejected. The remaining clean epochs were subsequently subjected to morlet wavelet decomposition to calculate event-related spectral power (ERSP) at 180 linearly spaced frequencies from 20 to 200Hz with wavelet cycles increasing from 3 to 10. This analysis was achieved using the newtimef function from the EEGlab MATLAB plugin (Schwartz Center and Computational Neuroscience). Briefly, post-stimulus power (0 to +100ms relative to the auditory stimulus) was normalised to baseline (-500 to 0ms relative to auditory stimulus) to generate an eventrelated spectral perturbation (ERSP) heat map. Evoked gamma power (dB) was then computed by averaging all values between 30 and 80Hz occurring 0 to 100ms relative the onset of the auditory stimulus.
Phase Coherence assessment
In addition to assessing local measures of oscillatory power, we also sought to assess phase coherence between the mPFC and dHPC, which reflects the strength of functional coupling between these regions. In order to measure this, we used the newcrossf function from the EEGlab MATLAB plugin (Delorme and Makeig, 2004) to derive the coherence spectrum using Welch's averaged periodogram method. Coherence values range from 0 -1, with lowest values indicative of complete independence between the two time series and highest values indicating identical phase synchrony between two signals. The raw LFP data from 10 to 30 minutes post-injection was segmented into 30s epochs containing both channels. Each epoch was then visually inspected and any epochs containing artefacts in either channel were rejected from subsequent analysis. Coherence spectra were calculated over the interval 1 to 200Hz. Gamma coherence was then calculated by averaging the coherence spectra over the interval between 30 and 80Hz.
J o u r n a l P r e -p r o o f
Histology After the experimental sessions were complete, and prior to culling, 2 seconds of DC current (1mA) was passed through active electrodes to facilitate deposition of ferrous ions from the stainless steel electrodes into the brain, as previously described (Li et al., 2018) . Mice were then euthanised via injection of pentobarbital (Lethabarb, Virbac Animal Health) and transcardially perfused with 0.1M phosphate-buffered saline followed by a formalin solution (4% paraformaldehyde/0.05% potassium ferrocyanide/0.05% potassium ferricyanide, Sigma-Aldrich). Brains were extracted and immersed in the same formalin solution for 24 hours at 4°C, after which they were transferred into cryoprotectant (30% sucrose) and stored for 3 days at 4°C. Brains were frozen in isopentane cooled over dry ice. Coronal brain sections (40µm) were cut on a cryostat with location of the electrode tips marked with a blue stain.
For all brains examined in this way, electrodes were correctly located ( Figure 7) .
Statistical analyses
In all cases, two-way repeated measures ANOVA (independent variables: genotype, drug) followed by Bonferonni post-hoc tests (where appropriate) were used to analyse data. The PV and CaMKIIα experiments were considered independent, and not directly statistically compared. All statistical analyses were performed using Graphpad Prism 6.0 (La Jolla, CA, USA). The data represent mean ± sem.
Results
Prepulse Inhibition
For the PV:GluN1 KO cohort, two-way ANOVA revealed a significant reduction in %PPI following MK-801 treatment (F (1, 14) =12.46, p=0.003), such that MK-801 impaired PPI.
J o u r n a l P r e -p r o o f
However, no significant effect of genotype (F (1, 14) =0.99,p=0.34) or genotype x treatment interaction (F (1, 14) =0.34, p=0.56; Figure 1A ) were found. When assessing the amplitude of the startle response, no significant effects were observed for genotype (F (1,14) =2.19, p=0.16), treatment (F (1, 14) =0.46, p=0.51) or interaction (F (1, 14) =0.59, p=0.45; Figure 1B ). In addition, no significant effects were observed for startle habituation for genotype (F (1,14) =0.70, p=0.41), treatment (F (1, 14) =3.90, p=0.06) or their interaction (F (1, 14) =0.16, p=0.69; Figure 1C ).
When assessing CaMKIIα:GluN1 KO mice, two-way ANOVA revealed a significant reduction in %PPI from MK-801 treatment (F (1, 25) =139.3, p<0.0001). In addition, we found a significant increase in %PPI in CaMKIIα:GluN1 KO mice relative to WT controls (F (1, 25) =6.95, p=0.014); however there was no significant interaction (F (1, 25) =0.10, p=0.75; Figure   1D ). Analysis of startle amplitude revealed a significant increase in startle due to MK-801 treatment (F (1, 25) =8.53, p=0.007), but no effect of genotype (F (1, 25) =3.69, p=0.066) was observed. However, a strong drug-genotype interaction was found (F (1, 25) =9.89, p=0.0042; Figure 1E ), indicating that MK-801 increases startle amplitude in WT mice, but not in CaMKIIα:GluN1 KO mice. MK-801 also significantly impaired startle habituation (F (1, 25) =24.95, p<0.0001; Figure 1F ), but no effect of genotype (F (1, 25) =0.09, p=0.76) or interaction (F (1, 25) =2.12, p=0.15) was observed. In summary, MK-801 impaired PPI but this was not affected by GluN1 deletion. In addition, CaMKIIα-GluN1 KO mice showed elevated PPI compared to WT.
Locomotor activity
We next sought to establish whether removal of GluN1 from PV+ cells or pyramidal neurons differentially impacted motor behaviours. In the PV:GluN1 cohort, a significant increase in locomotor activity due to MK-801 treatment was observed (F (3, 42) =17.79, p<0.0001; Figure   2A ), but this increase was significantly lower in PV:GluN1 KO mice compared to WT J o u r n a l P r e -p r o o f littermates (F (1, 14) =9.63, p=0.0078). Also, a significant drug-genotype interaction was revealed (F (3, 42) =5.56, p=0.003), due to desensitisation to the hyperlocomotor-inducing effects of MK-801 in PV:GluN1 KO mice. For the CaMKIIα:GluN1 KO mice, MK-801 treatment also increased locomotor activity (F (3,75) =50.16, p<0.0001; Figure 2B ), but no significant effect of genotype (F (1, 25) =0.89, p=0.36) or interaction (F (3, 75) =0.59, p=0.62) was observed, suggesting that locomotor activity was equally influenced by MK-801 regardless of GluN1 expression on CaMKIIα+ve cells. In summary, MK-801 increased locomotion in all strains, but this effect was impaired by GluN1 deletion from PV cells.
Behavioural observation
For the PV:GluN1 KO cohort only, we undertook a detailed analysis of several behavioural measures induced by MK-801 via observation: ataxia, stereotypies and catalepsy. We found significantly reduced ataxia due to MK-801 in PV:GluN1 KO mice relative to control littermates (F (1, 14) =45.26, p=0.0006; Figure 2C ). For stereotypies, MK801 induced stereotypic behaviour equally in both genotypes (F (1, 14) =0.04, p=0.92; Figure 2D ). Finally, for catalepsy, MK-801 dose-dependently increased levels of catalepsy (F (1, 14) =11.54, p=0.0003; Figure 2E ), with PV:GluN1 KO mice demonstrating strikingly higher levels of catalepsy when compared to WT littermates (F (1, 14) =55.35, p<0.0001). A significant drug-genotype interaction was revealed (F (1, 14) =6.53, p=0.003) due to profound sensitisation to the catalepsy-inducing effects of MK-801 in PV:GluN1 KO mice relative to controls. These behaviours were never observed in saline-treated mice.
Ongoing power analysis
To identify changes in ongoing oscillatory power, we recorded spontaneous LFPs in the mPFC and dHPC. PSD estimates for MK-801 treated mice compared to saline-treated mice J o u r n a l P r e -p r o o f showed noticeable differences, particularly in the gamma frequency range, but also, to a lesser extent in the beta band. Spectral density plots are provided in Figure 3A /B. Ongoing gamma power significantly increased in the dHPC following MK-801 treatment (F (1, 17) =29.8, p<0.0001; Figure 3C) , and a genotype effect was also revealed, with significantly lower levels of ongoing gamma power in the PV:GluN1 KO mice relative to control littermates (F (1, 17) =6.07, p=0.025). In addition, a significant drug-genotype interaction was observed (F (1, 17) =9.05, p=0.008), such that the MK-801-induced rise in ongoing gamma power was attenuated in PV:GluN1 KO mice relative to control littermates. A similar pattern was observed in the mPFC, with a significant drug effect found (F (1,18) =10.84, p=0.004; Figure 3D ). In addition, a significant genotype effect was observed, with ongoing gamma power being significantly reduced in PV:GluN1 KO mice relative to control littermates (F (1,18) =4.55, p=0.047). No significant interaction was revealed (F (1,18) =1.89, p=0.18).
Equivalent analyses were used to assess ongoing oscillatory activity in the CaMKIIα:GluN1 KO mice (see Figure 3E /F for PSD plots). In the dHPC, MK-801 significantly increased ongoing gamma power (F (1,16) =15.95, p=0.001; Figure 3G ), but we found no significant effect of genotype (F (1,16) =0.73, p=0.41). However a significant druggenotype interaction was revealed (F (1, 16) =8.19, p=0.011), as evidenced by the ineffectiveness of MK-801 to increase ongoing gamma power in CaMKIIα:GluN1 KO mice. Similar results were found in the mPFC, with significant effects of drug (F (1,16) =13.5, p=0.002; Figure 3H ), and significant drug x genotype interaction (F (1, 16) =8.43, p=0.010), without an effect of genotype (F (1,16) =0.09, p=0.76). In addition, when comparing only the saline-treated mice, in both regions, ongoing gamma power was significantly elevated in CaMKIIα:GluN1 KO mice compared to WT mice (mPFC: t (16) =2.13, p=0.048; dHPC: t (16) =4.09, p=0.0009). To summarise this outcome measure, MK-801 increased ongoing gamma power in both brain regions, but this was attenuated by removal of GluN1 from either PV or CaMKIIα cells.
J o u r n a l P r e -p r o o f ERSP analysis
Event related spectral perturbation (ERSP) associated with the auditory stimuli was assessed in both the mPFC and dHPC (visualised in Figures 4-5) . For the PV:GluN1 KO cohort, MK-801 significantly reduced evoked gamma power in the dHPC (F (1, 20) =23.98, p<0.0001; Figure 4B ) but there was no significant effect of genotype (F (1, 20) =2.02, p=0.17) or interaction (F (1, 20) =0.95, p=0.34) . Similarly, in the mPFC, MK-801 significantly reduced auditory evoked gamma power (F (1, 20) =4.50, p=0.047; Figure 4C ), but no significant effect of genotype (F (1, 20) =0.19, p=0.67) or interaction (F (1, 20) =3.084, p=0.09) was observed.
For the CaMKIIα:GluN1 KO cohort, MK-801 significantly reduced auditory evoked gamma power in the dHPC (F (1, 15) =182.6, p<0.001; Figure 5B ). In addition, CaMKIIα:GluN1 KO mice had significantly higher levels of evoked gamma power when compared to WT controls (F (1, 15) =11.48, p=0.0041), but no significant interaction was revealed (F (1, 15) =0.92, p=0.35). Similar results were obtained for the mPFC, with a significant reduction in evoked gamma power due to MK-801 treatment (F (1, 15) =119.4, p<0.0001; Figure 5C ) and significantly higher levels of evoked gamma power in CaMKIIα:GluN1 KO mice relative to controls (F (1, 15) =6.52, p=0.022) but no significant drug-genotype interaction (F (1, 15) =0.03, p=0.87). In summary, MK-801 reduced evoked power in all strains. In addition, CaMKIIα-GluN1 KO mice exhibited elevated evoked responses.
Coherence
We next assessed phase coherence between the dHPC and mPFC in all conditions. Notable differences in spectra between saline-treated and MK-801-treated mice were observed in both cohorts. For the PV:GluN1 KO mice (spectra in Figure 6A-B) , a significant increase in J o u r n a l P r e -p r o o f gamma coherence was observed for MK-801 treatment (F (1, 16) =4.92, p=0.041; Figure 6C ) but no significant genotype effect (F (1, 16) =0.13, p=0.72) or interaction (F (1, 16) =0.09, p=0.77).
For the CaMKIIα:GluN1 cohort (spectra in Figure 6D -E), MK-801 was also found to significantly increase gamma band coherence (F (1, 16) =5.09, p=0.038; Figure 6F ). However, we also observed a significant effect of genotype (F (1, 16) =5.96, p=0.026) and treatment x genotype interaction (F (1, 16) =6.30, p=0.023). Notably, whereas MK-801 produced a robust increase in gamma coherence in WT mice, the drug had no noticeable effect on gamma coherence in CaMKIIα:GluN1 KO mice.
Discussion
We set out to identify the cell type(s) responsible for electrophysiological consequences of NMDA receptor antagonism, focusing on 1) PV+ interneurons, and 2) CaMKIIα+ pyramidal neurons, and to relate these abnormalities to behavioural consequences of NMDAr hypofunction. Of note, previous work has used similar transgenic concepts to selectively delete NMDAr from either PV+ (Billingslea et al., 2014; Bygrave et al., 2016; Carlen et al., 2012) or CaMKIIα+ (Tatard-Leitman et al., 2015) neurons, and these mice display behavioural and electrophysiological phenotypes themselves, some of which were replicated here. In our study, we focused primarily on attempting to identify the cellular substrate driving the effect of NMDAr antagonists. In control mice, MK-801 caused disturbances to measures of local gamma synchrony in both the medial prefrontal cortex (mPFC) and dorsal hippocampus (dHPC)specifically an increase in the power of ongoing gamma oscillations, and a reduction in auditory evoked gamma oscillations, as shown previously in rodents (Anderson et al., 2017; Anderson et al., 2014; Hakami et al., 2009; Hudson et al., 2016; Jones et al., 2014; Jones et al., 2017; Lee et al., 2017; Olszewski et al., 2013; Pinault, 2008;  J o u r n a l P r e -p r o o f Journal Pre-proof Saunders et al., 2012a; Saunders et al., 2012b) . In addition, MK-801 increased gamma-band coherence between the mPFC and dHPC indicating an abnormal state of hyperconnectivity.
More importantly, these consequences of NMDAr antagonism were differentially regulated in PV:GluN1 KO mice and CaMKIIα:GluN1 KO. The drug-induced increase in ongoing gamma power was significantly attenuated in both PV:GluN1 KO mice and CaMKIIα:GluN1 KO mice, but deficits to auditory evoked gamma activity were unaffected by genotype.
Interestingly, in contrast to PV:GluN1 KO mice, the emergence of abnormal gamma band hyperconnectivity between the mPFC and dHPC following MK-801 treatment was completely absent in CaMKIIα:GluN1 KO mice. These findings suggest that while disturbances to local gamma synchrony can be caused by NMDAr antagonism on both PV interneurons and pyramidal neurons, NMDAr blockade on pyramidal neurons is crucial for inducing disturbances to long-range coherence and regional communication.
We also sought to investigate the necessity of these cell types on the behavioural disturbances caused by NMDA antagonists. Two of the most studied of these are hyperlocomotor activity and reduced PPI (Jones et al., 2011) . Hyperlocomotor effects of psychotomimetics such as NMDA antagonists are thought to be related to positive symptoms of schizophrenia (Jones et al., 2011) , whereas deficient PPI is a measure of impaired sensorimotor gating (Geyer et al., 2001) , both of which are consistently observed in patients with schizophrenia (Braff, 1993) . In WT mice, MK-801 administration produced hyperlocomotor activity as well as pronounced deficits to PPI as anticipated. MK-801 was equally effective at impairing PPI in all mouse strains, indicating that NMDA receptors located on either PV or CaMKIIα cells are not exclusively necessary for this behavioural consequence of NMDAr antagonism. Of note, previous assessment of PPI in PV:GluN1 KO mice also demonstrated similar levels of PPI in the mutant strain when compared to WT littermates (Bygrave et al., 2016) , a finding in line with the results of the present study.
J o u r n a l P r e -p r o o f
Together these results indicate NMDAr-mediated activity in either PV+ neurons or pyramidal neurons is not heavily involved in the modulation of PPI. By extension, this suggests that the impairment of PPI by NMDAr antagonists is not mediated by actions on PV+ neurons or pyramidal neurons. In order to account for the effects of NMDAr antagonists on PPI, other cell types are therefore likely to be involved. Of note, mice in which GluN1 was ablated from a larger, more diverse population of GABAergic interneurons expressing GAD67 were reported to have deficient PPI (Belforte et al., 2010) . While the population of GAD67+ cells do overlap with PV+ cells, they also include other interneuron subtypes, including somatostatin-positive interneurons and cholecystokinin-positive interneurons. Therefore, one interesting possibility is that NMDAr hypofunction on interneuron subtypes other than PV+ cells may cause the reductions in PPI observed following administration of NMDAr antagonists.
Interestingly, CaMKIIα:GluN1 KO mice showed enhanced PPI compared to WT and we have previously shown that PPI correlates with auditory evoked gamma oscillations (Hudson et al., 2016; Jones et al., 2014) , further strengthening this relationship. The elevated PPI in CaMKIIα:GluN1 KO mice was somewhat unexpected considering deficits in PPI have been reported in mice in which expression of GluN1 is reduced (GluN1 hypomorphic mice).
Transgenic mouse lines in which other NMDAr subunits have been ablated have also reported elevated PPI. For instance, NR2B KO mice have elevated PPI (Takeuchi et al., 2001 )and NR3A KO mice exhibit a transient elevation in PPI levels during prepubertal development (Brody et al., 2005) . Together, this suggests that the role played by NMDArmediated activity in PPI modulation is likely to be complicated and influenced by cellular expression, subunit composition and developmental stage.
In contrast to the consistent effects of MK-801 on PPI, locomotor activity was differentially influenced in the two strains. CaMKIIα deletion of GluN1 did not impact the J o u r n a l P r e -p r o o f hyperlocomotor effect of MK-801, but in PV:GluN1 KO mice, this phenotype was markedly attenuated when compared to control littermates. Of note, two previous studies have reported similar attenuation of NMDAr antagonist induced hyperlocomotor activity in PV:GluN1 KO mice (Bygrave et al., 2016; Carlen et al., 2012) . While this would appear to indicate that NMDAr on PV interneurons contribute to MK-801 effect on locomotor activity, an alternative interpretation is that our observation is due to supersensitisation of these mice to the behavioural effects of NMDAr antagonists (Bygrave et al., 2016) . NMDAr antagonistinduced effects on locomotor activity follow an inverted U-shape dose-response curve, whereby at sufficiently high doses, hyperlocomotor activity becomes superseded by increased ataxia and cataleptic behaviour. Indeed, in the current study, control mice showed a dosedependent increase in locomotor activity, tapering off at the highest dose. In contrast, in PV:GluN1 KO mice, no tapering off was observed, with the highest drug dose producing the highest level of locomotor activity, suggestive of no supersensitisation. We also consistently observed abnormal cataleptic behaviour in PV:GluN1 KO mice at higher doses of MK-801, a behaviour barely noticeable in control littermates at any dose, confirming previous observations (Bygrave et al., 2016) . While this may have influenced locomotor activity as measured, increasing doses of MK-801 produced more pronounced levels of catalepsy as well as further increases in locomotor activity in these mice. As such, our findings suggest that while PV:GluN1 KO mice do exhibit abnormal cataleptic-like activity following MK-801 treatment, the dose-response relationship for locomotor activity is indicative of a desensitisation to the hyperlocomotor effects induced by MK-801. Such findings indicate that the hyperlocomotor effects of MK-801 are heavily dependent on actions at PV+ neurons but not pyramidal neurons. These data also suggest that the locomotor and sensorimotor gating deficits caused by MK-801 are achieved via different cellular substrates.
In addition to behavioural measures, we also investigated the necessity of PV and CaMKIIα cells on the electrophysiological properties of NMDAr antagonism. In line with previous research, our findings confirm that MK-801 induces a significant increase in the power of ongoing gamma oscillations, as well as a significant reduction in the power of auditory evoked gamma oscillations in WT mice. Interestingly, in both PV:GluN1 KO mice and CaMKIIα:GluN1 KO mice, the MK-801 induced elevation in ongoing gamma power was substantially attenuated, compared to WT littermates. This suggests that NMDA hypofunction of parvalbumin neurons and pyramidal neurons can both contribute to this electrophysiological disturbance. Exactly how NMDAr hypofunction at these cell types may lead to an increase in ongoing gamma activity is not entirely clear. A recent optogenetics study (Chen et al., 2017) in which PV cells were selectively inhibited showed that this intervention led to an elevation in ongoing gamma activity, supporting the theory that reduced NMDAr mediated-excitation of PV cells is a potential mechanism by which NMDAr antagonists induce an elevation in ongoing gamma oscillations. While this might explain the attenuation to the MK-801 induced increase in ongoing gamma power in PV:GluN1 KO mice, it is less clear why deletion of NMDA receptors from pyramidal neurons resulted in a similar effect. Conventional views suggest that NMDAr antagonists preferentially influence activity in GABAergic interneurons, with alterations in pyramidal cell activity being an indirect downstream effectso-called disinhibition of neuronal activity (Homayoun and Moghaddam, 2007) . Our finding may be suggestive of some positive feedback loop which is disrupted by the deletion of NMDAr from CaMKIIα cells. Regardless of potential mechanism, our data does suggest that NMDAr hypofunction at pyramidal neurons is also sufficient to increase ongoing gamma power.
While oscillatory activity subserves an important role within local neuronal networks, it also plays an important role in the integration of coordinated activity between distant brain J o u r n a l P r e -p r o o f regions. Higher order cognition is reliant on efficient and accurate coordination of activity between distant brain regions and neuronal oscillations are one way in which interaction between distant neural networks can be achieved. In schizophrenia, abnormalities in longrange gamma coherence have been reported, although there has been some contrasting results (Jonak et al., 2016; Yeragani et al., 2006) . Such abnormalities in gamma coherence are thought to be indicative of disturbed functional connectivity. As such, in addition to investigating measures of local gamma synchrony, we also investigated whether gamma coherence between the mPFC and dHPC was disturbed following MK-801 treatment and the role of PV and CaMKIIα cells in this phenotype. We observed a striking effect of MK-801 on mPFC-dHPC gamma coherence, such that, in WT mice, MK-801 caused a state of abnormally high gamma band coherence between the mPFC and dHPC, indicating a state of hypersynchrony. This is in agreement with previous studies of NMDAr antagonists in rodents (Palenicek et al., 2011) and non-human primates (Slovik et al., 2017) . The neural mechanisms underlying this phenomenon are not clear. Presumably, in order to enable coordination of synchronous oscillatory activity between spatially discrete neural assemblies, a necessary requirement is anatomical connectivity. PV+ interneurons lack such long-range projecting processes, thereby making them unsuitable for directly facilitating connectivity on this scale. Consistent with this notion, we found that MK-801 was equally efficient at inducing hypersychrony in WT and PV:GluN1 KO, suggesting that NMDAr on PV cells do not contribute to this effect. In contrast, mPFC-dHPC coherence was not influenced at all by MK-801 in CaMKIIα:GluN1 KO mice, indicating that NMDAr hypofunction at pyramidal neurons is crucial for producing the state of hyper-coherent gamma activity between the mPFC and dHPC. Pyramidal neurons do exhibit long-range projections that could enable synchronisation to occur over such distances.
Numerous studies have attempted to elucidate the behavioural relevance of NMDAr antagonist induced gamma oscillatory abnormalities by conducting electrophysiological recordings during behavioural performance (Hudson et al., 2016; Jones et al., 2014; Jones et al., 2012; Leung and Ma, 2018) . Such studies have indicated that disturbances in different types of gamma oscillatory activity may be involved in different behavioural outcomes.
Specifically, it has been suggested that increases in ongoing gamma oscillations are directly relevant to the hyperlocomotor phenotype observed following administration of NMDAr antagonists (Anderson et al., 2014; Hakami et al., 2009) , whereas deficient evoked gamma responses may be more relevant to disturbances in sensory processing, including deficits in PPI (Hudson et al., 2016; Leung and Ma, 2018) .
In the present study, changes in PPI aligned well with changes in evoked gamma power. Specifically, the MK-801 induced reductions in evoked gamma power were observed regardless of genotype, and this was accompanied by similar reductions in PPI. In addition, following saline treatment, CaMKIIα:GluN1 KO mice exhibited elevated levels of evoked gamma power and this was accompanied by higher levels of PPI. This provides further evidence to support the claim that evoked gamma power is functionally linked to PPI performance. However, while PPI and evoked gamma power appeared to be closely related, the observation that MK-801 increases locomotor activity in the absence of increased ongoing oscillations in the CaMKIIα:GluN1 KO mice suggests that these two outcomes are not as intimately related as previously suggested (Anderson et al., 2014; Hakami et al., 2009) .
In contrast to measures of ongoing gamma power and gamma coherence, MK-801 was equally efficient at reducing auditory evoked gamma power in all mouse strains. This indicates that deficits in auditory evoked gamma activity caused by MK-801 are not likely to be reliant on direct drug actions on pyramidal neurons or PV+ neurons. These results support the concept that disturbances to evoked activity are mediated by different neuronal J o u r n a l P r e -p r o o f mechanisms to those governing disruptions to ongoing gamma activity, and also phase coherence. Our data also associate different behavioural outcomes to gamma oscillations:
ongoing gamma activity appears closely related to measures of drug-induced locomotor activity (Hakami et al., 2009; Jones et al., 2012) , whereas evoked gamma oscillations appear linked to sensorimotor gating behaviour (ie: PPI) (Hudson et al., 2016; Jones et al., 2014) .
The behaviours studied here do not phenotypically link to drug-induced changes in coherence, so further work needs to be done to examine other outcomes, such as cognitive phenotypes in these mice.
As alluded to above, we predicted modest phenotypic differences in our knockout mice, relative to wild-type littermates. This prediction was largely confirmed by our results, with the exception of an increase in evoked gamma power and PPI in CaMKIIα:GluN1 KO mice. Considering the influence of NMDAr-mediated transmission on excitatory tone of neurons, it is unclear why GluN1 ablation does not cause more marked changes. Of note, compensatory responses are often observed in knockout mouse strains, depending on the timing of genetic ablation relative to development. In CaMKIIα:Cre mice we use in our study (Casanova et al., 2001) , cre-recombinase is barely detectable in the first few postnatal days but increases throughout post-natal development until adult levels are observed at P15. On the other hand, cre-recombinase expression under the control of the PV promoter we use here switches on later, starting around weaning, and with maximal expression not achieved until 8 weeks (Carlen et al., 2012) . Therefore, in both the PV:GluN1 KO mice and the CaMKIIα:GluN1 KO mice, we expect normal expression of NMDA receptors throughout prenatal development, with deletion only occurring postnatally. It is therefore likely that compensatory changes during postnatal development may occur to partially reduce any effects of GluN1 ablation on neuronal physiology. Indeed, GluN1 ablation in other neuronal cell types has been shown to cause potentiation of synaptic AMPAr currents, which could be J o u r n a l P r e -p r o o f considered a compensatory response (Engblom et al., 2008; Zweifel et al., 2008) . It is therefore possible that similar compensatory changes may take place in PV+ neurons or CaMKIIα+ neurons lacking GluN1.
An important limitation to our research is the lack of in-house validation of the efficiency of success if the transgenic manipulations conducted. However, characterisation of the precise crosses used here has been performed previously conducted by other groups, which demonstrated cell-type specific reductions in NMDAr expression and function using cellular electrophysiology (Bygrave et al., 2016; Carlen et al., 2012; Tatard-Leitman et al., 2015) , in situ hybridisation (Tatard-Leitman et al., 2015) , and rt-PCR (Tatard-Leitman et al., 2015) . Nevertheless, it is important to consider this, and it would be valuable to also appreciate the consistency of GluN1 deletion from each specific cell in question.
To summarise, MK-801 induces electrophysiological and behavioural disturbances which may be relevant for the pathophysiology of schizophrenia. NMDAr hypofunctioninduced disturbances to local gamma synchrony can be mediated both by PV+ interneurons and pyramidal neurons, as mice lacking GluN1 expression selectively on either of these cell types exhibited a significantly attenuated rise in ongoing gamma power. However, GluN1 deletion from pyramidal neurons, but not PV+ neurons, abolished the elevated gamma coherence between the mPFC and dHPC produced by MK-801, indicating that the disturbances to coherence are mediated by drug actions directly on pyramidal neurons. The relationships of these electrophysiological mechanisms to behavioural disorders caused by MK-801 are complex: PPI appears to be closely tied to evoked gamma power, but not ongoing gamma power or regional gamma coherence, whereas hyperlocomotor activity appears to be unrelated to any measure of gamma activity. The results from the current study provide insight into the cellular mediators which link NMDAr hypofunction to gamma oscillatory dysfunction, indicating a role for both PV+ neurons and pyramidal neurons in J o u r n a l P r e -p r o o f mediating the MK-801 induced disturbances to local gamma synchrony, but a unique role for pyramidal neurons in inducing disturbances to long-range gamma coherence.
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The authors declare no conflicts of interest, financial or otherwise, associated with this work. significantly reduced PPI in WT and PV:GluN1 KO mice, but there was no effect of genotype. There was no effect of either drug, nor genotype on (B) the average magnitude of the startle response, or on (C) habituation to the startle response, although the effect of drug approached significance (p=0.06). In the CaMKIIα:GluN1 KO cohort, MK-801 also significantly impaired PPI (D), and we also observed a significant enhancement of PPI in CaMKIIα:GluN1 KO mice compared with WT littermates, but no interaction. (E) A significant interaction was observed for startle magnitude in this cohort, such that startle was increased by MK-801, but only in WT, and not in CaMKIIα:GluN1 KO mice. MK-801 dose-dependently increased locomotor activity, but this was significantly different between PV:GluN1 KO mice and WT mice. Also, a significant genotype x dose interaction was found, and post-hoc comparison revealed that a dose of 0.3mg/kg was significantly different. (B) In contrast, the locomotor-inducing effects of MK-801 were no different between CaMKIIα:GluN1 KO and WT littermates. (C) MK-801 also induced ataxia, but this was significantly greater in WT mice than PV:GluN1 KO mice, and a significant interaction was also observed. (D) No differences in genotype were found in MK-801-induced stereotypic behaviour, but (E) catalepsy was much more pronounced in PV:GluN1 KO mice than WT controls. Effect of genotype: ##p<0.01, ###p<0.001, ####p<0.0001; drug x genotype interaction: $p<0.05, $$p<0.01, $$$ p<0.001. Data reflects mean ± SEM. Sample sizes -PV cohort: WT=9; PV:GluN1 KO=7; CaMKIIα cohort: WT=13; CaMKIIα:GluN1 KO=14. When quantifying evoked gamma power in the ERSP, MK-801 significantly reduced gamma power resulting from the auditory click in both (B) hippocampus and (C) prefrontal cortex.
We also found that, in both regions, CaMKIIα:GluN1 KO mice exhibited significantly stronger evoked responses, compared to WT mice. Effect of drug: ****p<0.0001; effect of genotype: #p<0.05, ###p<0.001. Data reflects mean ± SEM. Sample sizes as for Figure 3 . Grand average coherence spectra generated from WT (A) and PV: GluN1 KO mice (B) following saline or MK-801 (1mg/kg) treatment. Quantifying gamma coherence found that J o u r n a l P r e -p r o o f MK-801 significantly increased coherence, but this was not influenced by genotype.
Coherence spectra for WT (E) and CaMKIIα:GluN1 KO mice (F) reveals a different influence of genotype. MK-801 treatment significantly increases gamma coherence (F), but this was only apparent in WT, and not CaMKIIα:GluN1 KO mice, as evidenced by significant drug x genotype interaction. Effect of drug: *p<0.05; effect of genotype: #p<0.05; drug x genotype interaction: $p<0.05. Data reflects mean ± SEM. Sample sizes -PV cohort: WT=8; PV:GluN1 KO=10; CaMKIIα cohort: WT=7; CaMKIIα:GluN1 KO=11. the Mouse Brain in stereotaxic coordinates (Paxinos and Franklin, 2004) Highlights:
NMDA receptor antagonists disrupt behaviour, and disturb normal electrophysiological rhythms in the brain, especially gamma oscillations.
Hyperlocomotor consequences NMDA receptor antagonists are mediated by parvalbumin interneurons and not excitatory cells Inhibition of NMDA receptors on both parvalbumin interneurons and excitatory cells contributes to elevations in ongoing gamma oscillations, but not evoked gamma oscillations. 
